Sedative News and Research RSS Feed - Sedative News and Research

A sedative is a substance that induces sedation by reducing irritability or excitement.
Opioid prescribing guidelines that focus high-dose use may need revision, say researchers

Opioid prescribing guidelines that focus high-dose use may need revision, say researchers

Overdoses of opioid pain medications frequently occur in people who aren't chronic users with high prescribed opioid doses--the groups targeted by current opioid prescribing guidelines, reports a study in the August issue of Medical Care. [More]
MIT researchers reveal key brainwave changes among patients receiving nitrous oxide

MIT researchers reveal key brainwave changes among patients receiving nitrous oxide

Nitrous oxide, commonly known as "laughing gas," has been used in anesthesiology practice since the 1800s, but the way it works to create altered states is not well understood. In a study published this week in Clinical Neurophysiology, MIT researchers reveal some key brainwave changes among patients receiving the drug. [More]
Finding may pave way for much-needed treatments for people with epilepsy

Finding may pave way for much-needed treatments for people with epilepsy

An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins. [More]
Teens start misusing ADHD drugs and other stimulants earlier than you might think

Teens start misusing ADHD drugs and other stimulants earlier than you might think

Despite stereotypes about college students resorting to black-market Ritalin to help them cram for exams, young people are actually most likely to start misusing prescription stimulant drugs in their high school years, according to new University of Michigan Medical School research. [More]
PAION initiates Remimazolam Phase 3 trial in patients undergoing colonoscopy

PAION initiates Remimazolam Phase 3 trial in patients undergoing colonoscopy

PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy. [More]
Study findings question benefit of giving sedatives before surgery for patients under general anesthesia

Study findings question benefit of giving sedatives before surgery for patients under general anesthesia

Although sedatives are often administered before surgery, a randomized trial finds that among patients undergoing elective surgery under general anesthesia, receiving the sedative lorazepam before surgery, compared with placebo or no premedication, did not improve the self-reported patient experience the day after surgery, but was associated with longer time till removal off a breathing tube (extubation) and a lower rate of early cognitive recovery, according to a study in the March 3 issue of JAMA. [More]
New study could lead to better remedies for insomnia, more effective anaesthetic drugs

New study could lead to better remedies for insomnia, more effective anaesthetic drugs

Scientists have discovered that switching on one area of the brain chemically can trigger a deep sleep. [More]

Hospira announces record fourth-quarter and FY 2014 results

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full year ended Dec. 31, 2014. [More]
Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine - better known as the anti-depressant Prozac - could hold the key to preventing PMS symptoms, an international team of researchers has found. [More]
Orexo announces positive results from ISTART/006 study

Orexo announces positive results from ISTART/006 study

Orexo US, Inc. announced results from the ISTART/006 study, being presented today at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry in Aventura, Florida, USA. [More]
Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Heart attack survivors often experience dangerous heart rhythm disturbances during treatment designed to restore blood flow to the injured heart muscle, a common and confounding complication of an otherwise lifesaving intervention. [More]
Large-scale study results of cardiac arrest cases now available on ScienceDirect

Large-scale study results of cardiac arrest cases now available on ScienceDirect

The results of a four-year international study of 2060 cardiac arrest cases across 15 hospitals published and available now on ScienceDirect. [More]
Study: Benzodiazepine sedatives may increase death risk in patients receiving mechanical ventilation

Study: Benzodiazepine sedatives may increase death risk in patients receiving mechanical ventilation

Sedation is frequently required for mechanically ventilated intensive care unit (ICU) patients to reduce anxiety, provide comfort, and assist in providing optimal respiratory support. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
Now, women experiencing morning sickness can benefit from Diclegis drug

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. [More]
FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. [More]
Research highlights widespread use of sleeping medication use among astronauts

Research highlights widespread use of sleeping medication use among astronauts

In an extensive study of sleep monitoring and sleeping pill use in astronauts, researchers from Brigham and Women's Hospital (BWH) Division of Sleep and Circadian Disorders, Harvard Medical School, and the University of Colorado found that astronauts suffer considerable sleep deficiency in the weeks leading up to and during space flight. [More]
New study finds highest rates of decline in prescription drug misuse nationwide

New study finds highest rates of decline in prescription drug misuse nationwide

Five states that have implemented multi-faceted prescription drug abuse prevention programs in recent years showed the highest rate of decline in prescription drug misuse rates nationwide, according to a new study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services. [More]
State highlights: N.C. lawmakers reach Medicaid agreement; Idaho asks SCOTUS to take up Medicaid reimbursement

State highlights: N.C. lawmakers reach Medicaid agreement; Idaho asks SCOTUS to take up Medicaid reimbursement

For the past few weeks, two big issues have kept the two chambers of the General Assembly from reaching an agreement on next year's state budget: teacher salaries and Medicaid. But on Wednesday, the Senate and the House of Representatives finally moved closer to agreement on their Medicaid forecasts, loosening a logjam that's kept legislators in Raleigh past July 1, the beginning of the fiscal year (Hoban, 7/3). [More]
Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals plc today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy. [More]
Advertisement
Advertisement